Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498185 · ClinicalTrials.gov registry record · Phase 2
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT01498185: Completed Phase 2 study, sponsored by AstraZeneca.
NCT01498185 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 171 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01498185, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
Primary Outcome
7-PGM was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the assessment on Day -1, prior to the start date and time of the first dose of the double-blind study medication. 7-PGM included the average of all available glucose values before and 2-hour (hr) after each meal (breakfast, lunch, dinner) as well as bedtime. Measurements were on Day -1, and Day 7 in the double-blind period.
Interventions
- DRUG Dapagliflozin
- DRUG Placebo matching Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01498185 record still lists
NCT01498185 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT01498185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01498185 about?
NCT01498185 is a clinical study titled "BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes". To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
What is the current status of trial NCT01498185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2012-02. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01498185?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo matching Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01498185?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01498185's enrollment target sits among peer trials
171 398th of 2000 higher than 1,602 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia